Bain Capital Public Equity Management II’s AstraZeneca AZN Stock Holding History

Bain Capital Public Equity Management II’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-157,494	Closed	-$15.7M	–	62
2020 Q4	$15.7M	Buy	+157,494	New	+$16.7M	0.8%	30
2020 Q3	–	Sell	-220,144	Closed	-$23.3M	–	45
2020 Q2	$23.3M	Buy	+220,144	New	+$22.7M	1.79%	19

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bain Capital Public Equity Management II's AZN Position: Q1 2021 in Review

Bain Capital Public Equity Management II sold out of AstraZeneca (AZN) in Q1 2021, closing a stake of 157,494 shares — an estimated $15.7M sold.

Bain Capital Public Equity Management II first reported a position in AZN in Q2 2020 and held it in 2 quarters. The position peaked at $23.3M in Q2 2020. 756 funds tracked by Wall St. Rank hold AZN as of Q1 2021.

Bain Capital Public Equity Management II reported no remaining AstraZeneca position as of Q1 2021 after selling out during the quarter.
Bain Capital Public Equity Management II sold 157,494 AstraZeneca shares in Q1 2021, an estimated $15.7M.
Bain Capital Public Equity Management II first reported a position in AstraZeneca in Q2 2020 and held it in 2 quarters.
Bain Capital Public Equity Management II's AstraZeneca position peaked at $23.3M in Q2 2020.
756 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2021.

Based on Bain Capital Public Equity Management II's 13F filing for Q1 2021, filed 17 May 2021.